Ohr Phase 2 Trial Shows Positive Results For OHR-102 In Retinal Vein Occlusion

(RTTNews) - Ohr Pharmaceutical, Inc. (OHRP), an ophthalmology research and development company, Monday announced positive final results from a Phase II investigator sponsored clinical trial of OHR-102 in patients with macular edema secondary to branch or BRVO and central retinal vein occlusion or CRVO.

After an initial 10 week combination therapy treatment period, patients who continued to receive a combination of topical OHR-102 BID plus Lucentis achieved greater visual acuity gains than the control group who received Lucentis alone.

At week 38, the mean gain in visual acuity from baseline for patients randomized to treatment with OHR-102 + Lucentis PRN was +27.8 letters compared with +23.3 for patients randomized to treatment with Lucentis plus PRN alone.

The data were presented by John Wroblewski, a retina specialist at Cumberland Valley Retina Consultants on July 11 at the 2015 Annual Meeting of the American Society of Retina Specialists in Vienna, Austria.

The trial was designed to determine the effect of OHR-102 in eyes with macular edema secondary to retinal vein occlusion.